Clinical Trial VICCNCBMT12108


A Non-Myeloablative Conditioning and Transplantation of Partially HLA-Mismatched and HLA-Matched Bone Marrow for Patients with Sickle Cell Disease and Other Hemoglobinopathies

Principal Investigator(s)

Adetola Kassim


  • Protocol No. VICCNCBMT12108
  • Open Date: 05/08/2013
  • Staging: NA
  • Age Group: Both Child and Adult
  • Scope: Local
  • Objective: Obtain estimates of transplant-related mortality (TRM) and progression-free survival in patients with severe hemoglobinopathies receiving non-myeloablative conditioning and transplantation of partially human leukocyte antigen (HLA)-mismatched bone marrow from first-degree relatives (mini-haploBMT) as well as HLAmatched donors.
  • Disease Sites: Sickle Cell
  • Therapies: Therapy (NOS)
  • Drugs: Cyclophosphamide (CTX); Filgrastim (GCSF); Fludarabine (Fludara); Mesna; Sirolimus; Thymoglobulin
  • Participating Institutions: Vanderbilt University
  • National Clinical Trial ID: NCT01850108
  • Secondary Protocol No: Not Specified



Learn More

You do not have JavaScript enabled. This site works better with JavaScript turned on.